Publications by authors named "Patricia Cordero Ruiz"
Article Synopsis
- A 62-year-old woman developed symptoms including fever and weight loss after starting RYR, resulting in a diagnosis of mixed hepatocellular and cholestatic acute hepatitis, along with positive autoimmune liver serology.
- Treatment involved discontinuing RYR, leading to a gradual improvement in liver function, indicating that certain patients may experience liver injury from RYR due to toxic or immunogenic effects, warranting careful consideration of hepatotoxicity.
The course of progressive liver damage after achieving sustained virological response (SVR) with direct-acting antivirals (DAAs) remains undetermined. We aimed to determine risk factors associated with the development of liver-related events (LREs) after SVR, focusing on the utility of non-invasive markers. An observational, retrospective study that included patients with advanced chronic liver disease (ACLD) caused by hepatitis C virus (HCV), who achieved SVR with DAAs between 2014 and 2017.
View Article and Find Full Text PDFHepatitis C virus (HCV) one-step diagnosis improves recovery in patients with active infection. However, patients with previous anti-HCV+ may be excluded. We aimed to identify and retrieve non-referred or lost-to-follow-up HCV-infected patients.
View Article and Find Full Text PDFIntroduction: patients with advanced chronic liver disease (CLD) may be at an increased risk of a severe course due to cirrhosis-associated immune dysfunction. The aim of this study was to determine the prevalence of CLD in COVID-19 patients and to analyze the course of the infection, compared with patients with non-liver disease.
Materials And Methods: this was a retrospective single center study of all patients with a positive SARS-CoV-2 polymerase chain reaction (PCR) test from March 23rd to April 30th, 2020.
Introduction: several barriers remain in the hepatitis C care cascade, which need to be removed in order to eliminate chronic hepatitis C. These barriers include deficiencies in screening and confirmatory diagnosis as well as difficulties in accessing treatment.
Aims: to identify factors associated with the non-referral of patients with positive hepatitis C virus (HCV) antibodies and to identify factors associated with loss of follow-up or non-attendance of these patients to specialist consultation after referral.
Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Eur J Gastroenterol Hepatol
July 2017
Background And Goals: The slow progression of chronic hepatitis C (CHC) infection requires long observation periods to detect clinical changes. We compare the incidence of clinical events, hepatocellular carcinoma (HCC), overall mortality, liver-related mortality, and fibrosis progression between patients with a sustained virological response (SVR) and nonresponders (NR) after a 13-year follow-up period.
Study: One hundred and eighty-two CHC patients, who received interferon and ribavirin treatment between 1996 and 2000, were included.
Background: in most cases, inflammatory bowel disease (IBD) debuts at reproductive age. The data available in the literature show infliximab (IFX) to be a safe drug during pregnancy but there is very little evidence about the activity of the disease following drug withdrawal during pregnancy.
Aims: determine the drug's safety in pregnant women in our setting and assess its effect on the foetus, drawing on the experience of several hospitals.